Cryoport, Inc.
For the period ended Jun 5, 2026. Filed Apr 22, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 5, 2026 · Filed Apr 22, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|---|
| ☒ | Definitive Proxy Statement |
|---|
| ☐ | Definitive Additional Materials |
|---|
| ☐ | Soliciting Material Under §240.14a-12 |
|---|
CRYOPORT, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|
| ☐ | Fee paid previously with preliminary materials |
|---|
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
|---|
2026 Proxy Statement
| CHAIR LETTER | Dear Fellow Stockholders, |
|---|---|
| 2025 was a year of strong progress for Cryoport. We advanced our mission of supporting life and health by delivering reliable, comprehensive temperature-controlled supply chain solutions for the life sciences. Through continued innovation, investment in advanced technologies, expansion of our global supply chain network, and the dedication of our highly skilled team, we broadened our service offerings, introduced new products, expanded our geographic footprint, and onboarded new clients – all while moving our company further along our “pathway to profitability.” | |
| Financial Performance We delivered full-year revenue of $176.2 million, exceeding the high end of our guidance and marking 12% year-over-year growth, reflecting continued momentum across our core markets. | |
| Growth was largely fueled by both clinical and commercial Cell & Gene Therapy (CGT) activity. Commercial CGT revenue increased 29% year-over-year to a record $33.4 million and clinical trial revenue grew 14% to $47.1 million. These results reflect the acceleration of CGT patients being treated on a global basis and the life sciences industry’s reliance on Cryoport’s capabilities. | |
| At the end of the year Cryoport supported a record 760 clinical trials and 20 commercial therapies globally, representing approximately 70% of all CGT - industry clinical trials. | |
| Life Sciences Services Our Life Sciences Services business continued to expand in 2025, and represented approximately 55% of total revenue, compared to approximately 52% in 2024. Our Life Sciences Services revenue was $96.5 million, up 18% year-over-year. It included BioStorage/BioServices revenue of $18.4 million as clients increasingly turned to Cryoport for integrated, end-to-end support. We believe our leadership position across both clinical and commercial CGT programs, and the breadth of the CGT development pipeline we support, provide a substantial foundation for sustained long-term growth as we move forward. | |
| We also increased our investments the Life Sciences Services segment by strategically investing to support the traction that we are seeing across our broad portfolio of CGT clients. These targeted investments include the launch of our Global Supply Chain Center in Paris, France, the continued buildout of our Global Supply Chain Center in Santa Ana, California (consolidating three existing facilities), and the expansion of our BioServices operation on our campus near Liege, Belgium. |
| Cryoport Inc | 2026 Proxy Statement |
|---|
Life Sciences Products Our Life Sciences Products business grew revenue by 7% during 2025, ending the year at $79.7 million. MVE Biological Solutions (MVE) makes up most of this revenue and continues to play a leading role in the cryogenic systems market globally. In addition to supporting our Services businesses, with its focus on innovation, MVE continues to further enhance its position as the global leader in the production of high-quality cryogenic systems.
Partnerships and CollaborationsIn 2025, we formed a strategic partnership with the DHL Group, which included DHL’s acquisition of CRYOPDP. This strategic partnership will support DHL’s 2030 strategy in healthcare and, over time, we believe it will enhance our positioning in the APAC and EMEA regions and strengthen our competitive industry profile. In addition, as part of our continuing strategic initiative to embed our market leading solutions into the CGT ecosystem and improve our growth trajectory, we expanded our global partnerships by entering into strategic collaborations with Cardinal Health and Parexel.
InnovationIn 2025, we undertook another transformative step by establishing our Enterprise Technology Group (“ETG”). ETG is designed to transform Cryoport into a stronger technology powered life sciences platform by embedding advanced digital capabilities across all our global temperature-controlled supply chain services and products. In the future, rather than operating as a series of discrete services, ETG will enable Cryoport to deliver integrated, end to end supply chain management solutions that connect data, operations, and decision making across every touchpoint.
ETG’s mission is to lower operational costs, improve efficiency, and unlock new products, services, and provide data driven insights for our customers by automating processes and improving visibility. This approach enhances reliability, reduces risk, and helps simplify supply chain complexity for clients operating in the highly regulated, temperature-controlled environments within the life sciences.
By leveraging generative artificial intelligence (“AI”), advanced analytics, and other emerging technologies, ETG will enable Cryoport to scale faster, differentiate more effectively, and build the future of intelligent temperature-controlled supply chain management for the life sciences.
Outlook for 2026: Positioned for Another Year of GrowthWe believe we enter 2026 with a strong balance sheet and a clear pathway to future profitability. We are currently forecasting 2026 revenue of $190 million to $194 million. Additionally, as of December 31, 2025 and based on internal and external data, we are anticipating nine (9) new therapy approvals, two (2) additional approvals for label or geographic expansion,
and thirteen (13) BLA/MAA filings in 2026. This growing pipeline, paired with our expanding global supply chain center network and operational investments, support a highly encouraging outlook.
Closing Thoughts I am proud of the tireless efforts of the entire Cryoport team of employees as each day each of them strives to improve the conditions of lives for many thousands of patients around the world through our efforts to: help cure conditions that threaten life; support the sustaining of life through protein production from animal husbandry; and assist in helping create life for those needing medical assistance through our unparalleled support of reproductive medicine.
I want to extend my deepest gratitude to our employees, clients, and long-term shareholders for their unwavering support and dedication. The fulfillment of our vision is important as it is to the benefit of mankind. Together, we are making a meaningful impact on the development of the Cell & Gene Therapy industry and the broader evolution of the Life Sciences industry. Daily, we are helping improve the health of lives around the world.
Sincerely yours,
/s/Jerrell Shelton
Jerrell Shelton Chairman, President and CEO
| NOTICE OF ANNUAL MEETING OF STOCKHOLDERSTo Be Held June 5, 2026 | Dear Fellow Stockholders: | |
|---|---|---|
| We cordially invite you to virtually attend the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Cryoport, Inc., a Nevada corporation (the “Company”), which will be held on Friday, June 5, 2026, at 10:00 a.m. CDT. The Annual Meeting will be hosted online. You will be able to attend the Annual Meeting, vote and submit your questions during the meeting via a live webcast by visiting www.virtualshareholdermeeting.com/CYRX2026. There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. | ||
| The Annual Meeting will be held for the following purposes: | ||
| 1. | To elect six directors; |
| 2. | To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2026; |
| 3. | To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our proxy statement for the Annual Meeting; |
| 4. | To approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to, among other things, increase the number of authorized shares under the plan; and |
| 5. | To transact such other business as may properly come before the meeting or any adjournment thereof. |
The Board of Directors has fixed the close of business on Monday, April 6, 2026 as the record date for the determination of stockholders who are entitled to notice of and to vote at the meeting, or any adjournments thereof.
On or about April 22, 2026, we began mailing a Notice of Internet Availability of Proxy Materials (the “Notice”) to holders of our common stock and holders of our Series C Convertible Preferred Stock as of the record date instead of a printed copy of the proxy materials. The Notice provides instructions on how to access our proxy materials on the Internet and how to obtain printed copies. We urge you to read the information contained in the proxy materials carefully.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JUNE 5, 2026.
The proxy statement for the Annual Meeting and accompanying Annual Report on Form 10-K for the year ended December 31, 2025 are available via the Internet at www.proxyvote.com.
Whether or not you plan to virtually attend the Annual Meeting, it is important that your shares be represented and voted. You may vote before the meeting by Internet, by phone, or by mail by following the instructions on the Notice.
You may also vote during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/CYRX2026 and entering the 16-digit control number included in your Notice, on your proxy card or in the instructions that accompanied your proxy materials.
Sincerely,
/s/Jerrell Shelton
Jerrell Shelton Chairman, President and CEO
YOUR VOTE IS IMPORTANT. YOU ARE URGED TO VOTE YOUR PROXY PROMPTLY BY MAIL, BY TELEPHONE OR VIA THE INTERNET, WHETHER OR NOT YOU PLAN TO VIRTUALLY ATTEND THE ANNUAL MEETING.
Table of Contents
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.